Dermira, Inc. (NASDAQ:DERM)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research report issued on Tuesday. They currently have a $46.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 55.46% from the stock’s previous close.

Several other research analysts have also commented on DERM. Mizuho initiated coverage on Dermira in a report on Thursday, March 30th. They set a “buy” rating and a $42.00 price target on the stock. BidaskClub upgraded Dermira from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cantor Fitzgerald initiated coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock. Finally, Evercore ISI initiated coverage on Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $43.80.

Dermira (NASDAQ:DERM) traded down 0.57% during midday trading on Tuesday, reaching $29.42. 76,757 shares of the company were exchanged. Dermira has a 52 week low of $25.63 and a 52 week high of $38.75. The firm’s 50 day moving average price is $28.34 and its 200-day moving average price is $31.26. The stock’s market capitalization is $1.22 billion.

COPYRIGHT VIOLATION WARNING: “Dermira, Inc. (NASDAQ:DERM) Given Buy Rating at Needham & Company LLC” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/18/dermira-inc-nasdaqderm-given-buy-rating-at-needham-company-llc.html.

In related news, SVP Christopher M. Griffith sold 1,312 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $27.07, for a total value of $35,515.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,312 shares of company stock worth $468,441. 13.30% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of DERM. FMR LLC raised its stake in shares of Dermira by 10.1% in the fourth quarter. FMR LLC now owns 4,710,737 shares of the biopharmaceutical company’s stock worth $142,877,000 after buying an additional 433,601 shares during the period. BlackRock Inc. raised its stake in shares of Dermira by 4,816.7% in the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock worth $115,729,000 after buying an additional 3,323,841 shares during the period. TimesSquare Capital Management LLC raised its stake in shares of Dermira by 6.8% in the first quarter. TimesSquare Capital Management LLC now owns 2,588,661 shares of the biopharmaceutical company’s stock worth $88,299,000 after buying an additional 164,950 shares during the period. Jennison Associates LLC raised its stake in shares of Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock worth $73,539,000 after buying an additional 860,597 shares during the period. Finally, Eagle Asset Management raised its stake in shares of Dermira by 242.0% in the third quarter. Eagle Asset Management now owns 2,491,800 shares of the biopharmaceutical company’s stock worth $58,158,000 after buying an additional 1,763,103 shares during the period. Institutional investors own 84.58% of the company’s stock.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.